Acrivon Therapeutics (ACRV) will be providing ACR-368 and ACR-2316 clinical data and other updates via a press release at 7:30 a.m. ET, and conference call and webcast at 8:30 a.m. ET, both on Thursday, January 8. Topics will include: Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the planned confirmatory Phase 3 trial; Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, including safety data, dosing regimen, and early clinical activity across AP3-prioritized solid tumor types; Nomination of new preclinical development candidate, including target disclosure, for Acrivon’s AP3-driven cell cycle program.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon to provide ACR-368, ACR-2316 clinical data in January
- Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
- 3 Best Stocks to Buy Now, 11/14/2025, According to Top Analysts
- Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
- Acrivon Therapeutics Reports Q3 2025 Financial Results